This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Amidephrine is a sympathomimetic indicated in the treatment of acute, chronic, vasomotor, and allergic rhinitis.
- Generic Name
- Amidephrine
- DrugBank Accession Number
- DB16623
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Amidephrine (DB16623)
- Weight
- Average: 244.31
Monoisotopic: 244.088163557 - Chemical Formula
- C10H16N2O3S
- Synonyms
- Amidefrine
- Amidephrine
- External IDs
- MJ-1996
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Allergic rhinitis (ar) ••• ••• •••••••• • ••••• Treatment of Chronic rhinitis ••• ••• •••••••• • ••••• Treatment of Vasomotor rhinitis ••• ••• •••••••• • ••••• Treatment of Acute rhinitis ••• ••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The therapeutic efficacy of Amidephrine can be decreased when used in combination with Acebutolol. Alfuzosin The therapeutic efficacy of Amidephrine can be decreased when used in combination with Alfuzosin. Amitriptyline The therapeutic efficacy of Amidephrine can be decreased when used in combination with Amitriptyline. Amitriptylinoxide The risk or severity of hypertension can be increased when Amitriptylinoxide is combined with Amidephrine. Amoxapine The therapeutic efficacy of Amidephrine can be decreased when used in combination with Amoxapine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Amidephrine mesylate S3IG39T94B 1421-68-7 INSXAGGBFMXUIH-UHFFFAOYSA-N
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7E2P22546V
- CAS number
- 37571-84-9
- InChI Key
- ZHOWHMXTJFZXRB-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H16N2O3S/c1-11-7-10(13)8-4-3-5-9(6-8)12-16(2,14)15/h3-6,10-13H,7H2,1-2H3
- IUPAC Name
- N-{3-[1-hydroxy-2-(methylamino)ethyl]phenyl}methanesulfonamide
- SMILES
- CNCC(O)C1=CC(NS(C)(=O)=O)=CC=C1
References
- General References
- BASG: Fentrinol - Nasentropfen (Amidephrine) Nasal Drops [Link]
- External Links
- ChemSpider
- 14288
- ChEBI
- 134994
- ChEMBL
- CHEMBL146408
- Wikipedia
- Amidephrine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution / drops; suspension / drops Nasal 1 mg/ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -1.2 Chemaxon pKa (Strongest Acidic) 9.91 Chemaxon pKa (Strongest Basic) 9.25 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 78.43 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 61.95 m3·mol-1 Chemaxon Polarizability 25.2 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-002b-0390000000-287ec1c30364929091e3 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-0090000000-d1df19f0c3467b81be75 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-0910000000-bb6e409d2fa98166b523 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-002f-5590000000-397dfedd8b7b365b7e24 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0apj-1900000000-3e41ecfaf84783930c71 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9200000000-773d8772762aadb847f0 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 150.48601 predictedDeepCCS 1.0 (2019) [M+H]+ 152.84401 predictedDeepCCS 1.0 (2019) [M+Na]+ 158.93715 predictedDeepCCS 1.0 (2019)
Drug created at February 24, 2021 21:33 / Updated at April 30, 2021 13:08